select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Lupus Nephritis-Pipeline Review, H2 2015

Lupus Nephritis-Pipeline Review, H2 2015


  • Products Id :- GMDHC7244IDB
  • |
  • Pages: 112
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Lupus Nephritis-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Lupus Nephritis-Pipeline Review, H2 2015', provides an overview of the Lupus Nephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Lupus Nephritis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Lupus Nephritis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Lupus Nephritis Overview 9

Therapeutics Development 10

Pipeline Products for Lupus Nephritis-Overview 10

Pipeline Products for Lupus Nephritis-Comparative Analysis 11

Lupus Nephritis-Therapeutics under Development by Companies 12

Lupus Nephritis-Therapeutics under Investigation by Universities/Institutes 15

Lupus Nephritis-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Lupus Nephritis-Products under Development by Companies 19

Lupus Nephritis-Products under Investigation by Universities/Institutes 21

Lupus Nephritis-Companies Involved in Therapeutics Development 22

AbbVie Inc. 22

Asahi Kasei Pharma Corp. 23

Azano Pharmaceuticals Inc. 24

Biogen, Inc. 25

Bristol-Myers Squibb Company 26

Deltanoid Pharmaceuticals Inc. 27

F. Hoffmann-La Roche Ltd. 28

FibroStatin SL 29

GlaxoSmithKline Plc 30

HanAll Biopharma Co., Ltd. 31

Invion Limited 32

Millennium Pharmaceuticals, Inc. 33

Ocata Therapeutics, Inc. 34

Zyrnat Biotherapeutics SL 35

Lupus Nephritis-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

abatacept-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

belimumab-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

BIIB-023-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BMS-986147-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

DP-001-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

FSMAB-26-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

HL-161-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

INV-103-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ixazomib citrate-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

mizoribine-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Monoclonal Antibody for Lupus Nephritis-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

obinutuzumab-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

P-Dex-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

RO-5461111-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Stem Cell Therapy for Autoimmune Diseases-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

venetoclax-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

voclosporin-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Y-175L-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

ZY-11-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Lupus Nephritis-Recent Pipeline Updates 81

Lupus Nephritis-Dormant Projects 103

Lupus Nephritis-Discontinued Products 105

Lupus Nephritis-Product Development Milestones 106

Featured News & Press Releases 106

Aug 24, 2015: Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis 106

Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 106

Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 107

Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 107

May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH 108

Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease 109

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

Number of Products under Development for Lupus Nephritis, H2 2015 10

Number of Products under Development for Lupus Nephritis-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd...1) 20

Products under Investigation by Universities/Institutes, H2 2015 21

Lupus Nephritis-Pipeline by AbbVie Inc., H2 2015 22

Lupus Nephritis-Pipeline by Asahi Kasei Pharma Corp., H2 2015 23

Lupus Nephritis-Pipeline by Azano Pharmaceuticals Inc., H2 2015 24

Lupus Nephritis-Pipeline by Biogen, Inc., H2 2015 25

Lupus Nephritis-Pipeline by Bristol-Myers Squibb Company, H2 2015 26

Lupus Nephritis-Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015 27

Lupus Nephritis-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 28

Lupus Nephritis-Pipeline by FibroStatin SL, H2 2015 29

Lupus Nephritis-Pipeline by GlaxoSmithKline Plc, H2 2015 30

Lupus Nephritis-Pipeline by HanAll Biopharma Co., Ltd., H2 2015 31

Lupus Nephritis-Pipeline by Invion Limited, H2 2015 32

Lupus Nephritis-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 33

Lupus Nephritis-Pipeline by Ocata Therapeutics, Inc., H2 2015 34

Lupus Nephritis-Pipeline by Zyrnat Biotherapeutics SL, H2 2015 35

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Stage and Target, H2 2015 38

Number of Products by Stage and Mechanism of Action, H2 2015 40

Number of Products by Stage and Route of Administration, H2 2015 42

Number of Products by Stage and Molecule Type, H2 2015 44

Lupus Nephritis Therapeutics-Recent Pipeline Updates, H2 2015 81

Lupus Nephritis-Dormant Projects, H2 2015 103

Lupus Nephritis-Dormant Projects (Contd...1), H2 2015 104

Lupus Nephritis-Discontinued Products, H2 2015 105

List of Figures

Number of Products under Development for Lupus Nephritis, H2 2015 10

Number of Products under Development for Lupus Nephritis-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Products, H2 2015 18

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Top 10 Targets, H2 2015 37

Number of Products by Stage and Top 10 Targets, H2 2015 37

Number of Products by Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Top 10 Routes of Administration, H2 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 41

Number of Products by Top 10 Molecule Types, H2 2015 43

Number of Products by Stage and Top 10 Molecule Types, H2 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Asahi Kasei Pharma Corp.

Azano Pharmaceuticals Inc.

Biogen, Inc.

Bristol-Myers Squibb Company

Deltanoid Pharmaceuticals Inc.

F. Hoffmann-La Roche Ltd.

FibroStatin SL

GlaxoSmithKline Plc

HanAll Biopharma Co., Ltd.

Invion Limited

Millennium Pharmaceuticals, Inc.

Ocata Therapeutics, Inc.

Zyrnat Biotherapeutics SL

Lupus Nephritis Therapeutic Products under Development, Key Players in Lupus Nephritis Therapeutics, Lupus Nephritis Pipeline Overview, Lupus Nephritis Pipeline, Lupus Nephritis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com